




Immunogenetic characterization of clonal plasma cells in systemic
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To the Editor:
Sequence-based analysis has come to play an integral role
in many hematological malignancies [1], but disorders such
as systemic light-chain (AL) amyloidosis remain poorly
characterized due to its low incidence and small tumor size
[2, 3]. Thus, greater knowledge about the immunogenetic
landscape of AL amyloidosis is required since, for example,
potential differences between the genomic profiles of AL
amyloidosis and multiple myeloma (MM) could help
identifying patients with monoclonal gammopathies at
greater risk of developing AL amyloidosis and monitor
presymptomatic organ damage [4, 5].
To gain further insight into the immunogenetic landscape
of AL amyloidosis, we performed whole-exome sequencing
(WES) on highly purified bone marrow clonal plasma cells
(PCs) isolated by fluorescence activation cell sorting
(FACS) based on patient-specific aberrant phenotypes. A
total of 27 patients with confirmed new diagnosis of AL
amyloidosis based on the presence of amyloid-related sys-
temic syndrome, positive amyloid tissue staining with
Congo red, restricted light-chain deposition by
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immunohistochemistry or mass spectometry, and evidence
of PC clonality were investigated. Patients’ demographics
and clinical characteristics are described in Supplementary
Table 1. PCs were collected and processed in triplicates
followed by whole genome amplification of samples with
genomic DNA amounts <50 ng (Supplementary Table 2).
Afterwards, library construction, exome enrichment, and
sequencing were performed individually. An overall aver-
age depth of 63× and mean on-target coverage of 84% were
obtained. Data were deposited in the Sequence Read
Archive of the NCBI (http://www.ncbi.nlm.nih.gov/sra)
under the PRJNA596656 access number. To increase spe-
cificity, only single-nucleotide variants (SNVs) and indels
detected by both Strelka [6] and Varscan2 [7] variant callers
were selected. Moreover, only somatic mutations present in
two of three libraries per patient were considered positive.
Germline variants were excluded through WES of matched
peripheral blood cells. The mutational profile of patients
with AL amyloidosis was compared with that of patients
with MM enrolled in CoMMpass (n= 930; IA13c dataset).
The CNVKit [8] was used to determine copy number
abnormalities (CNA) from WES data (in 21 of the 27 AL
patients). Deep sequencing of B-cell receptor immunoglo-
bulin (BcR Ig) gene rearrangements was performed in all
patients as previously described [9], and compared with that
of a series of 62 newly diagnosed MM patients. Detailed
methodology is available in the Supplementary methods.
We identified a total of 718 exonic, non-immunoglobu-
lin, nonsynonymous mutations with a variant allelic fraction
(VAF) >5% (683 SNV and 35 indel). Total number and
type of mutations are described in Supplementary Fig. 1.
Interestingly, mutational burden was significantly correlated
with patients’ age (R= 0.51, p < 0.001) (Supplementary
Fig. 2) though not tumor burden (data not shown). Only 37
out of 662 (5.5%) mutated genes were altered more than
once (Fig. 1). That notwithstanding, 23 of the 27 cases
(85%) presented with at least one mutation in one of the 37
genes (range, 1–11); being FAT4, IGLL5, MUC16, and
SSH2 the most frequently mutated genes (≥3 patients). With
a median of 18 mutations per sample (range, 8–92), patients
with AL amyloidosis are closer to monoclonal gammopathy
of undetermined significance (MGUS) (median of 19) [10]
rather than MM (median of 38 in the CoMMpass IA13c
dataset, p < 0.0001; Fig. 2a) in terms of mutational load. By
contrast, the presence of CNA was more frequent in
AL amyloidosis (19/21, 90.5%; Supplementary Fig. 3) than
MGUS (60.6% in Mikulasova et al.) [10] and similar to
MM patients (virtually 100%) [11]. Overall, these results
underpin recent observations based on the immunopheno-
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Fig. 1 Genes recurrently mutated in AL. Distribution per patient of the most frequently mutated genes (n= 37). Boxes were colored according
to the type of mutation. Top barplots define the total number of mutations per patient.
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amyloidosis in the crossroad between MGUS and MM also
in genetic grounds. Of note, the only alterations associated
with inferior progression-free survival were gains in chro-
mosomes 9 and 19 (Supplementary Fig. 4a, b), whereas del
(13q) was associated with higher NT-proBNP levels (Sup-
plementary Fig. 5). Furthermore, patients with +1q also
displayed greater risk of cardiac involvement (Supplemen-
tary Table 3).
Interestingly, various MM-defined driver mutations [12]
were undetected in patients with AL amyloidosis (e.g.,
NRAS, BRAF, and TRAF) or observed only once (e.g., DIS3
and DUSP2), most of them being subclonal with a median
VAF of 23% (Supplementary Fig. 6) that was unrelated to
the lower tumor burden in AL amyloidosis due to the
FACSorting strategy used to isolate clonal PCs, as descri-
bed above. Simultaneous analysis of ours and the CoMM-
pass datasets unveiled that out of 14,135 mutated genes,
only 608 (4.4%) were shared between AL amyloidosis and
MM (Fig. 2b), with considerable differences in their
recurrence (Fig. 2c). Of note, none of the 65 genes exclu-
sively mutated in AL amyloidosis were recurrent. Further-
more, only four genes (XKR5, PRSS45, PKD1L2, and
SRRM5) overlapped with the 105 described by Boyle et al.
[3] as AL restricted. While the results from these two stu-
dies suggest that MM recurrent mutations are unfrequently
detected in patients with AL amyloidosis, recent data based
on WES and targeted sequencing reported by Huang et al.
[13] identified recurrent mutations in KRAS. Furthermore,
IGLL5 emerged as one of the most commonly mutated
genes in ours and the latter series, but not in that analyzed
by Boyle et al. We have found no association between
mutated genes and patients’ outcome, whereas Huang et al.
identified three mutated genes with prognostic value.
Altogether, further studies in larger series of patients are
warranted to shed more light into the mutational landscape
and potential clinical correlations in AL amyloidosis.
In the absence of a unifying genetic event defining AL
amyloidosis, BcR Ig gene rearrangements emerge as an
alternative to understand the propensity for the deposition of
monoclonal Ig light-chains in the form of β-sheet fibrils, as
well as organ tropism. Previous studies based on PCR
amplification of individual (typically Lambda) light-chain
variable gene (VL) families have shown a potential bias in
germline donor use in patients with AL amyloidosis [14]
and that VL gene usage may influence clinical presentation,
organ deposition, and outcome [15, 16]. Hence, we per-
formed next-generation sequencing (NGS) of Ig heavy
chain gene (IGH) and Kappa light-chain (IGK) rearrange-
ments both in patients with AL amyloidosis (n= 27) and
MM (n= 63) to provide complementary information on
IGH and IGK repertoires, clonal variability, and extent of
somatic hypermutations. A total of 39 IGHV-D-J and IGK-
V-J clonotypes were identified and 5 of the 27 (19%)










































































Fig. 2 The mutational landscape in AL and MM. a Number of
mutations in patients with newly diagnosed AL and MM. b Shared and
private mutations between AL and MM. c Driver genes based in its
recurrence in AL and MM. d Predominant Ig heavy chain gene rear-
rangements used in AL and MM.
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clonal rearrangements. This extent of clonal heterogeneity
differs (p= 0.024) from that found in our MM series (3.9%).
Using a cut-off of 98% to define homology, 9 of
39 sequences (23%) in AL amyloidosis were considered as
mutated, which is slightly less when compared with that
found in MM (36%). The CDR3 length was not significantly
different between AL amyloidosis and MM (median of 54
versus 51 amino acids). The most frequent IGH gene
involved in AL amyloidosis was IGHV3-48 (recurrence of
10.3%) and 100% of patients who have this rearrangement
had kidney involvement (p= 0.025) (Supplementary
Table 4), whereas IGHV3-30 was the most recurrent (12%)
in MM (Fig. 2d). Thus, expression of IGHV3-48 adds up to
IGLV6-57 as germline Ig genes associated with dominant
kidney deposition [14, 15]. Of note, we found no significant
differences regarding IGH and IGK repertoires, clonal
variability, and extent of somatic hypermutations between
patients with light-chain only versus heavy- and light-chain
M-component (data not shown).
This study confirms previous observations that AL
amyloidosis cannot be defined by a singular or a set of well-
defined genetic events. In fact, based on combined results
from WES of 99 patients (27 in this study, 24 in Boyle et al.
[3], and 48 in Huang et al. [13]), 63 genes were found to be
recurrently mutated. By contrast, our study further supports
the notion that germline Ig gene use is a key determinant in
the pathogenesis of AL amyloidosis [16], and unveils novel
associations of cytogenetic abnormalities with organ
involvement and outcome. The extent of CNA was similar
between AL and MM, but MM-driver genes were not
recurrently mutated in AL, which instead was marked by
greater clonal heterogeneity (i.e., similarly to MGUS) [10].
Taken together with differential predominance of IGH
rearrangements, our results suggest that amongst other
factors, Ig germline genes rather than specific cytogenetic
abnormalities predispose light-chains from a PC clone to
adopt an aberrant conformation, typically closer to patients’
MGUS stage before the development of higher tumor bur-
den and accumulation of MM-driver mutations. Given the
high frequency of Lambda light-chain deposition in AL,
further studies are warranted to investigate if clonal muta-
tions in IGLL5 (median VAF, 64%) contribute to this pro-
cess. In such cases, its detection together with other
candidate genes (e.g., FAT4, MUC16, and SSH2) through
NGS diagnostics could emerge as novel risk markers for AL
amyloidosis in patients with monoclonal gammopathies.
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